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Abstract 
Background: Human mesenchymal stem cells (hMSCs) therapy has recently been considered a promising treatment 
for atopic dermatitis (AD) due to their immunomodulation and tissue regeneration ability. In our previous studies, we 
demonstrated that hMSCs alleviate allergic inflammation in murine AD model by inhibiting the activation of mast 
cells and B cells. Also our phase I/IIa clinical trial showed clinical efficacy and safety of hMSCs in moderate‑to‑severe 
adult AD patients. However, hMSCs therapy against atopic dermatitis have had poor results in clinical field. Therefore, 
we investigated the reason behind this result. We hypothesized that drug–cell interaction could interfere with the 
therapeutic efficacy of stem cells, and investigated whether coadministration with pimecrolimus, one of the topical 
calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood mesenchymal stem 
cells (hUCB‑MSCs) in AD.
Methods: hUCB‑MSCs were subcutaneously injected to AD‑induced mice with or without pimecrolimus topical 
application. To examine whether pimecrolimus influenced the immunomodulatory activity of hUCB‑MSCs, hUCB‑
MSCs were treated with pimecrolimus.
Results: Pimecrolimus disturbed the therapeutic effect of hUCB‑MSCs when they were co‑administered in murine 
AD model. Moreover, the inhibitory functions of hUCB‑MSCs against type 2 helper T (Th2) cell differentiation and 
mast cell activation were also deteriorated by pimecrolimus treatment. Interestingly, we found that pimecrolimus 
decreased the production of  PGE2, one of the most critical immunomodulatory factors in hUCB‑MSCs. And we dem‑
onstrated that pimecrolimus downregulated COX2‑PGE2 axis by inhibiting nuclear translocation of NFAT3.
Conclusions: Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs 
in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell 
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Background
Atopic dermatitis (AD) is a chronic and relapsing skin 
disorder characterized by eczematous skin lesions with 
severe pruritus and epidermal barrier dysfunction [1]. 
As the incidence of AD increased, impacting approxi-
mately 20% of children and 3% of adults worldwide, it has 
become a major public health issue [2]. The pathogen-
esis of AD is characterized by excessive type 2 helper T 
(Th2) cell-mediated inflammation, resulting in increased 
serum levels of total IgE and skin barrier dysfunction. 
IgE-mediated mast cell degranulation induces the release 
of inflammatory mediators that recruit lymphocytes and 
eosinophils to skin lesions [3]. The aim of the AD clini-
cal management of is to improve symptoms (pruritus 
and dermatitis), prevent exacerbations, and minimize 
therapeutic risks such as bacterial infections. The basic 
management consists of epidermal barrier repair with 
emollients and anti-inflammatory drugs such as corti-
costeroids or calcineurin inhibitors. Calcineurin inhibi-
tors are one of the most common medications prescribed 
for patients with AD [4–6]. These drugs bind to FK506-
binding protein-12 (FKBP-12), inhibit the serine/threo-
nine phosphatase calcineurin, and subsequently prevent 
nuclear translocation of nuclear factor of activated T cells 
(NFAT). Consequently, NFAT-mediated transcription of 
proinflammatory cytokines in T cells is suppressed [7]. 
However, these classical drugs are insufficient to resolve 
severe AD or exert significant undesirable side effects [8, 
9].
Currently, mesenchymal stem cell (MSC)-based ther-
apy has appeared to be a promising approach to alleviate 
many diseases, including AD. MSCs are capable of self-
renewing and able to differentiate into multiple lineages 
for damaged tissue regeneration [10]. Additionally, MSCs 
have been considered as an immunomodulator through 
the regulation of the proliferation, recruitment and func-
tion of innate and adaptive immune cells. In our previous 
studies, we showed that subcutaneously administered 
human MSCs (hMSCs) effectively alleviate experimental 
AD in a mouse model by inhibiting mast cell degranula-
tion through prostaglandin E2  (PGE2) and TGF-beta [11]. 
In the same mouse model of AD, we documented that 
IV-infused hMSCs significantly reduce disease sever-
ity by suppressing B cell proliferation and maturation 
through cyclooxygenase 2 (COX2) [12]. Furthermore, 
the development and application of cellular therapies 
using hMSCs for AD are ongoing, and the hMSC ther-
apy is regarded as a potential candidate for the treatment 
of AD. We first reported a marked improvement of AD 
phenotypes of patients who received MSC therapeutics 
in our phase I/IIa clinical trial [13]. During the clini-
cal trial period, no serious adverse events occurred, and 
none of the patients discontinued the trial due to adverse 
events. The results showed the clinical efficacy of human 
umbilical cord blood-derived mesenchymal stem cells 
(hUCB-MSCs) in a dose-dependent manner in adult 
patients with moderate-to-severe AD. In particular, 55% 
of patients in the high-dose group showed a 50% reduc-
tion in the EASI score. The IGA score and SCORAD 
score in the high-dose group also decreased by 33% and 
50%, respectively.
However, in contrast to expectations, most clinical tri-
als using MSCs have produced ambiguous results and 
these controversial experimental outcomes have been 
considered a major obstacle towards their widespread 
clinical application for AD [14]. Therefore, we tried 
to elucidate the reasons why the different results were 
obtained. Several limitations of hMSC therapy, such as 
poor engraftment, survival or donor variation, are sug-
gested as reasons for the discrepancy. Many studies have 
reported enhancement strategies to resolve these prob-
lems, including preconditioning and genetic modifica-
tion [15–17], although these approaches have yet to be 
confirmed in the clinic field. Furthermore, a combina-
tion strategy might be one of the reasons why the clinical 
application of hMSCs is complicated. Therefore, a more 
comprehensive analysis of coadministration with other 
drugs is needed to establish standardized guidelines for 
efficient hMSC therapy.
In this study, we hypothesized that the other drugs 
administered with hMSCs during the clinical trial might 
have interacted with hMSCs. We investigated whether 
the combined application of hMSCs and calcineurin 
inhibitors limits the therapeutic effect of cell therapy in 
subjects with AD. In the AD mouse model, the combi-
nation group showed no or a lower therapeutic effect 
than the group treated with only hUCB-MSC injection. 
The coculture of hUCB-MSCs and AD-related immune 
cells, such as Th2 cells and mast cells, also showed a 
decreased suppressive effect induced by pimecrolimus. 
NFAT3 in hUCB-MSCs functioned as a transcription 
factor of COX2, one of the important factors for the 
therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs 
therapy and facilitate the widespread application of hMSCs in clinical field.
Keywords: Atopic dermatitis, Stem cell therapy, Combination therapy, Calcineurin inhibitor, NFAT signaling, COX2‑
PGE2 axis
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immunomodulation of MSCs, and pimecrolimus may 
lower the therapeutic effect of hUCB-MSCs by inhibit-
ing the nuclear translocation of NFAT3 in hUCB-MSCs. 
Here, for the first time, we documented the negative 
effects of combination therapy of hUCB-MSCs with 
other medicines and suggested enhancement strategies 
for the clinical application of hUCB-MSCs.
Methods
Mice & induction of AD in NC/Nga mice
All animal experimental procedures were approved by 
the Seoul National University Institutional Animal Care 
and Use Committee (IACUC No. SNU-191122-1-1) in 
accordance with the guidelines of the committee. NC/
Nga mice (male, seven‐week‐old) were purchased from 
Central Lab Animal Inc. (Seoul, Republic of Korea). Mice 
were housed in a temperature- and humidity-controlled 
room in the animal facility of Seoul National Univer-
sity. A total of 23 mice were used. They were divided 
into groups of 5: NC (Negative control group, N = 3), 
PC (Positive control group/Df-induced group, N = 5), 
Pimecrolimus (Df-induction + Pimecrolimus, N = 5), 
MSC (Df-induction + hUCB-MSCs, N = 5), MSC + Pime. 
(or hUCB-MSC + Pime, Df-induction + hUCB-
MSCs + Pimecrolimus, N = 5). For induction of AD in 
NC/Nga mice, hair was removed from the lower part of 
the ear to the upper part of the tail and, NC/Nga mice 
were left undisturbed for 24 h. Then, 100 mg/head of Df 
(Dermatophagoides farinae; Biostir-AD, Biostir, Kobe, 
Japan) was applied evenly with a cotton swab to the 
depilated back and the back of the ear twice a week, for 
three weeks (total of six times). The test substance was 
administered on the 3rd day after the last induction (day 
20). A total of 2 ×  106 hUCB-MSCs were equally sub-
cutaneously administered at five locations of lesions on 
each mouse. Pimecrolimus (Elidel® cream 1%) was also 
administered once a day for 7 days from day 20 until day 
26. It was applied to the lesion at a dose of 0.2  g/head. 
Mice were sacrificed on day 27, and blood, ear and dorsal 
skin were collected. The experimental schedule is shown 
in Fig.  1a. The severity of the skin lesion was evaluated 
three times a week one week after the first induction. It 
was evaluated by the clinical visual evaluation method 
and symptoms were scored from 0 to 3 points (0: none, 1: 
mild, 2: moderate and 3: severe). Skin lesion severity was 
reported as a total score for the following four symptoms: 
erythema, scarring/dryness, edema, and erosion.
Histopathological evaluation
Ears and dorsal skin of mice were removed and fixed with 
4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, 
USA). Fixed tissues were embedded in paraffin. Paraffin‐
embedded samples were serially sectioned at a thickness 
of 5  μm. Sections were stained with hematoxylin and 
eosin (H&E) or toluidine blue. Slides were observed 
under a Nikon Eclipse Ti‐U microscope (Nikon, Tokyo, 
Japan). The epidermal thickness of the dorsal skin and ear 
was measured in H&E-stained sections, and the number 
of mast cells was counted in toluidine blue-stained dorsal 
skin sections.
Cytokine measurement
Blood was collected from the mice in a BD microtainer 
tube (BD Bioscience, San Jose, CA, USA) via cardiac 
puncture and centrifuged at 3500  rpm for 15  min. The 
supernatant was harvested in a fresh 1.5 ml conical tube. 
The serum IgE level was measured using a Mouse IgE 
Uncoated ELISA Kit (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions.
Conventional RT‑PCR and quantitative real‑time PCR
Total RNA was extracted from cultured cells and in vivo 
tissues using TRIzol reagent (Invitrogen). cDNA syn-
thesis was performed using Superscript™ III reverse 
transcriptase (Invitrogen). For conventional RT-PCR, 
the first-strand cDNA was amplified with primer sets 
for NFAT family member and COX2. The mRNA lev-
els of each gene were normalized using GAPDH as the 
housekeeping gene. After adequate cycles, aliquots of 
each sample were electrophoresed on 1.5% agarose gels 
(w/v) with 1X GelRed (Hayward, CA, USA) to visualize 
gels under UV light. Quantitative Real-time PCR was 
performed using SYBR-Green PCR Master Mix with 
an Applied Biosystems 7500 Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). The Quan-
titative Real-time PCR reaction was carried out with 
initial denaturation conditions at 50 °C for 2 min and at 
95 °C for 10 min followed by at 95 °C for 15 s and 60 °C 
for 1 min for 60 cycles. All the reactions were performed 
in triplicate independently three times and the obtained 
results were normalized against the GAPDH housekeep-
ing gene. The expression levels of major inflammatory 
cytokines in lesioned ear skin of mice, TARC and IL-22, 
were measured for comparative analysis. Also, in  vitro 
experiment, the expression level of TNF in LAD-2 cell, 
GATA3, STAT6 and IL-13 in Th2 cell and COX2 in 
hUCB-MSCs were measured. The primer sequences and 
conditions used in this study are presented in Additional 
file 4: Table S1.
Cell culture
hUCB‐MSCs were provided by the Kangstem Biotech 
GMP Center (Gwangmyeong, Republic of Korea). All 
experiments using hUCB-MSCs were approved by 
the IRB of the Public Institutional Bioethics Commit-
tee designated by the South Korea Ministry of Health 
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and Welfare (Approval No. P01-201605-BS-02) with 
informed maternal consent. hUCBs were obtained 
from 4 donors and total 4 lines of hUCB-MSCs were 
established. hUCB‐MSCs were cultured in KSB-3 
complete media (Kangstem Biotech, Seoul, Republic 
of Korea) containing 10% fetal bovine serum (Gibco 
BRL, Grand Island, NY, USA). We used hUCB‐MSCs 
under passage 6 for all experiments. For mononuclear 
cell culture and Th2 cell isolation, human periph-
eral blood mononuclear cells were purchased from 
Lonza (Lonza, Basel, Switzerland) and they were cul-
tured in RPMI 1640 (Gibco) supplemented with 10% 
fetal bovine serum. The human mast cell line LAD-2, 
which was kindly provided by Dr. D. D. Metcalfe of 
the Center for Cancer Research, National Institutes of 
Health (Bethesda, MD, USA), was cultured as previ-
ously described [12]. Briefly, the cells were cultured in 
StemPro-34 serum-free medium supplemented with 
1X GlutaMAX (Gibco BRL), 100  ng/ml recombinant 
human stem cell factor (rhSCF, Peprotech, Rock Hill, 
NJ, USA) and antibiotics.  In in  vitro culture experi-
ment, hUCB-MSC + Pime group means the cells that 
cocultured with hUCB-MSCs and pimecrolimus.
Fig. 1 Simultaneous administration of pimecrolimus and hUCB‑MSCs deteriorates therapeutic effects of MSCs against atopic dermatitis. AD was 
induced in NC/Nga mice by repetitive exposure to Df extract in the dorsal and ear regions for 3 weeks. Each group of mice was monitored and 
sacrificed on day 27 for further analysis. a Schematic of the experimental course of AD induction in mice. b Representative gross images of dorsal 
and ear lesions. c Clinical severity was assessed by scoring dryness, excoriation, erythema and edema. The Kruskal–Wallis test with Dunn’s post 
hoc test was used to assess the significance of differences in scoring index at day 27. N = 3–5 mice per group. n.s: not significant and *P < 0.05. The 
results are shown as the mean ± SD
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MTT assay
hUCB‐MSCs were seeded at a density of 3 ×  104 cells 
per well in a 24-well cell culture plate. After 24  h of 
incubation, hUCB‐MSCs were treated with serial ten-
fold dilutions of pimecrolimus (Sigma-Aldrich, 0.1 ng/
ml – 10  μg/ml) for 72  h. After treatment, cells were 
incubated with 500  μl of MTT solution (0.5  mg/ml) 
for 4  h. After incubation, MTT solution was removed 
and 500  μl of DMSO was added to dissolve insoluble 
formazan crystal. Then, the plate was read immediately 
and the absorbance of each well was measured at wave-
length of 570 nm using an Infinite200 PRO microplate 
reader (Tecan, Maennedorf, Switzerland).
Cell cycle assay
After hUCB‐MSCs were treated with pimecrolimus 
(0.01 ng/ml, 1 ng/ml, 100 ng/ml) for 3 days, cells were 
harvested and washed with PBS twice and fixed with 
ice-cold 70% ethanol at -20℃ for over 30  min. Fixed 
cells were washed with PBS and suspended in 400  μl 
PBS, containing RNase A (final concentration 6.25 μg/
ml) and Propidium iodide (final concentration 50  μg/
ml). After incubation in 37℃ for 30 min, cell cycle anal-
ysis was performed using a FACSCalibur flow cytom-
eter and Cell Quest software (BD Bioscience).
Flow cytometry
To assess the effect on hUCB-MSCs, hUCB-MSCs were 
treated with 100 ng/ml pimecrolimus for 3 days. After 
treatment, trypsinized cells were incubated with a flu-
orochrome-conjugated antibody and analyzed. The fol-
lowing antibodies were used: FITC Mouse Anti-Human 
CD45, PE Mouse Anti-Human HLA-DR, FITC Mouse 
anti-Human CD105, APC Mouse anti-Human CD73, 
APC Mouse Anti-Human CD29, FITC Mouse Anti-
Human CD44, PE Mouse Anti-Human CD36 and PE 
Mouse Anti-Human CD34. Whole antibodies were pur-
chased from BD Bioscience. Fluorescence was detected 
with a FACScalibur flow cytometer and evaluated using 
Cell Quest software (BD Biosciences).
Measurement of the secretion of IDO‑1 from hUCB‑MSCs
hUCB-MSCs were seeded in a 6-well cell culture plate at a 
density of 1.5 ×  105 cells per well. After 24 h of incubation, 
we treated IFN-γ (20 ng/ml) to hUCB-MSCs for 72 h with 
or without pimecrolimus (0.01 ng/ml, 1 ng/ml, 100 ng/ml) 
to detect the secretion of IDO-1. Cell lysates were extracted 
with cell lysis buffer. Human IDO1/IDO ELISA Kit (LsBio, 
Seattle, WA, USA) was used for measurement of IDO-1 
concentration following the manufacturer’s instruction.
Measurement of the secretion of  PGE2 and TGF‑beta 
from hUCB‑MSCs
Secretion or production of  PGE2 and TGF-beta from 
hUCB-MSCs was quantified using ELISA kits in accord-
ance with the manufacturer’s instructions. hUCB-MSCs 
were seeded in a 6-well cell culture plate at a density of 
1.5 ×  105 cells per well. After 24 h of incubation, hUCB‐
MSCs were treated with pimecrolimus (0.01  ng/ml, 
1  ng/ml, 100  ng/ml) for 72  h. The media was collected 
and centrifuged at 2500  rpm for 5  min to eliminate 
cell debris. The concentrations were determined using 
Human TGF‐β1 Quantikine ELISA (R&D Systems, Min-
neapolis, MN, USA) and Human  PGE2 Quantikine ELISA 
(R&D Systems).
Cell proliferation assay
A total 3 independent cell proliferation assay experiments 
were conducted. (1) To assess the effect of pimecrolimus 
against the proliferation of hUCB-MSCs, hUCB-MSCs 
were seeded at a density of 1.5 ×  104 and pimecrolimus 
(0.01  ng/ml, 1  ng/ml, 100  ng/ml) was treated for 72  h 
after attachment of cells. (2) To assess the suppression 
ability of hUCB-MSCs to mononuclear cell prolifera-
tion, we conducted coculture experiment of hUCB-MSCs 
and mononuclear cell. hUCB-MSCs were seeded at a 
density of 1.5 ×  104 (1:10) per well in a 96-well cell cul-
ture plate. After attachment of hUCB-MSCs, 1.5 ×  105 
human peripheral blood mononuclear cells (hPBMCs, 
Lonza) were seeded per well with ConA (5  μg/ml) and 
cultured for 5 days. During 5 days, hPBMCs were treated 
with pimecrolimus (100  ng/ml) with or without hUCB-
MSCs. (3) To assess the suppression ability of hUCB-
MSCs to mast cell proliferation, we conducted coculture 
experiment of hUCB-MSCs and LAD-2 cells. hUCB-
MSCs were seeded at a density of 1.5 ×  104 (1:10) per 
well in a 96-well cell culture plate. After attachment of 
hUCB-MSCs, 1.5 ×  105 LAD-2 were seeded per well and 
cultured for 24 h. Proliferation was detected by a bromo-
deoxyuridine (BrdU) ELISA kit (Roche, Indianapolis, IN, 
USA). After culture, BrdU labeling solution (100 μM) was 
added. The culture medium containing BrdU solution 
was removed after overnight incubation at 37  °C, and 
the cells were fixed with FixDenat solution for 30 min at 
room temperature. After fixation the cells were incubated 
with an anti-BrdU-POD working solution for 90 min at 
room temperature. Following three washing steps, a sub-
strate solution was added to the cells and incubated for 
5–30  min at room temperature. After sufficient color 
development, the OD values were read at 450  nm on a 
microplate reader (TECAN, Zürich, Switzerland). Within 
the coculture experiment, we have calibrated the prolif-
eration of hPBMCs and LAD-2 cells by subtracting OD 
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values of hUCB-MSCs cultured wells from OD values of 
cocultured wells.
Th2 and hUCB‑MSC coculture
We conducted a coculture experiment with hUCB-MSCs 
and Th2 cells to assess inhibitory effect of hUCB-MSCs 
on Th2 cell differentiation. hUCB-MSCs (3 ×  104) were 
seeded on a Transwell membrane (pore size 8 μm; Corn-
ing, Bedford, MA, USA).  CD4+ T cells were purified 
from human peripheral blood mononuclear cells (Lonza) 
using a human  CD4+ T cell isolation kit (Miltenyi Biotec, 
Bisley, UK) according to the manufacturer’s instructions. 
After the attachment of hUCB-MSCs, 5 ×  105  CD4+ 
T cells were cultured in the well beneath the insert for 
5 days. Cells were cultured with RPMI 1640 medium con-
taining 10% heat-inactivated fetal bovine serum, Dyna-
beads Human T-Activator CD3/CD28 (Gibco BRL), IL-2 
(20 ng/ml), IL-4 (20 ng/ml) and IL-6 (20 ng/ml) to induce 
Th2 differentiation. All recombinant human cytokines 
were purchased from Peprotech. For 5 days,  CD4+ T cells 
were treated with pimecrolimus (100 ng/ml) at the indi-
cated concentrations with or without hUCB-MSCs. After 
5 days of coculture, Th2 differentiation was analyzed by 
detecting the levels of the CD4 (FITC mouse anti-human 
CD4; BD Biosciences) and IL-4 (PE mouse anti-human 
IL-4; BD Biosciences) proteins using a FACSCalibur flow 
cytometer and Cell Quest software (BD Biosciences).
Beta‑hexosaminidase assay
hUCB-MSCs (1.5 ×  105 per well) were seeded in 24-well 
cell culture plates and incubated for 24 h. After incuba-
tion, 1.5 ×  105 LAD-2 human mast cells were added and 
sensitized with 100 ng/ml human myeloma IgE (Merck-
Millipore, Burlington, MA, USA) for 24 h with or with-
out pimecrolimus (100 ng/ml). The next day, LAD-2 cells 
were washed and challenged with 3 μg/ml goat anti-IgE 
(polyclonal antibody, Merck-Millipore) for 1  h. After 
challenge, the induction of mast cell degranulation was 
stopped on ice, and supernatants were harvested after 
centrifugation. The supernatant (60 μl) was transferred to 
a 96‐well plate and mixed with an equal volume (60  μl) 
of 7.5  mM ρ‐nitrophenyl‐Ν‐acetyl‐β‐d‐glucosaminide 
substrate solution (dissolved in 0.05  M citric acid, pH 
4.5, Sigma-Aldrich). The mixture was incubated in a 
shaking incubator (120  rpm) for 2  h at 37  °C, and then 
120 μl of 0.2 M glycine (pH 10.7) was added. The absorb-
ance at 410 nm was measured using a microplate reader 
(TECAN). The release of β‐hexosaminidase was calcu-
lated as the percentage of the total β‐hexosaminidase 
content in stimulated mast cells, as determined by lysing 
cells in buffer containing 0.1% Triton X‐100.
Western blotting
Whole-cell lysates were prepared with the protein lysis 
buffer Pro-prep (Intron biotechnology, Gyeonggi, Korea), 
and nuclear and cytosolic fractionation was conducted 
as described previously [18]. The concentration of pro-
tein was measured using a Bio-Rad DC protein assay kit 
(Bio-Rad Laboratories, Hercules, CA, USA), with bovine 
serum albumin (BSA) as the standard. For each pro-
tein sample, a 10 μg aliquot was separated by 8% or 10% 
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred to a nitrocellulose mem-
brane. After blocking with 3% BSA in Tris-buffered saline 
(TBS-T), the blots were probed overnight at 4  °C with 
the following primary antibodies: COX2 (Cell Signaling 
Technology, Beverly, MA, USA, 12282, 1:1000), NFAT3 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, 
sc-271127, 1:200), p-NFAT3 (Santa Cruz Biotechnology, 
sc-135771, 1:200), Lamin A/C (Santa Cruz Biotechnol-
ogy, sc-7292, 1:200), Alpha tubulin (Abcam, ab18251, 
1:1000), GAPDH (Merck-Millipore, MAB374, 1:2000). 
After washing the membranes with TBS-T (three times, 
5  min each), the membranes were blotted with second-
ary antibodies at room temperature for 1 h. The proteins 
were detected with enhanced chemiluminescence (ECL) 
reagent (GE Healthcare Life Science, Buckinghamshire, 
UK).
Immunocytochemistry staining
After the treatments indicated in each figure legend, 
hUCB-MSCs were fixed with 4% paraformaldehyde at 
room temperature for 10  min, permeabilized by 0.05% 
Triton X-100 solution for 10  min and blocked with 5% 
normal goat serum for 1 h. The cells were subsequently 
stained with specific primary antibodies against COX2 
(Abcam, Cambridge, MA, USA, ab15191, 1:100) and 
NFAT3 (Santa Cruz Biotechnology, 1:50) at 4℃ for 
overnight. The cells were then incubated with Alexa 
488-labeled secondary antibodies (Molecular Probes, 
Eugene, OR, USA; 1:1000) for 1 h at room temperature. 
For counterstaining, nuclei were stained with DAPI. The 
images were captured by a confocal microscope (Nikon, 
Eclipse TE200).
Statistical analysis
The mean values of all data are presented as the 
means ± SD. The significance of differences in the data 
was determined using Kruskal–Wallis test with Dunn’s 
post hoc test for multiple groups and is indicated in the 
figure legends. Statistical analyses were performed using 
GraphPad Prism version 7.0 (GraphPad Software, San 
Diego, CA, USA).
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Results
Combined administration of hUCB‑MSCs 
with pimecrolimus adversely affects the therapeutic 
potential of hUCB‑MSCs against AD mouse model
As a calcineurin inhibitor, pimecrolimus is one of the 
most common anti-inflammatory drugs used to treat AD. 
We first investigated whether pimecrolimus influences 
the therapeutic effect of hUCB-MSCs on AD. As for AD 
mouse model, we used a Df-induced murine AD model. 
Df extract was repeatedly applied onto the dorsal surface 
and ear of NC/Nga mice twice a week for three weeks 
(Fig. 1a). As mentioned in our previous studies [12, 16], 
2.0 ×  106 hUCB-MSCs were subcutaneously injected per 
head on day 20 when AD was fully induced. Pimecroli-
mus was topically administered once a day from day 20 
until sacrifice. Compared to the negative control group, 
the Df-induced group exhibited itching, erythema, and 
hemorrhage on the dorsal skin and ear, followed by 
edema, excoriation, erosion, scaling, and dryness of the 
skin (Fig.  1b). The affected area was alleviated in the 
hUCB-MSC-injected group, but the hUCB-MSC + Pime 
group were slightly improved. For quantification, we reg-
ularly evaluated the clinical severity until day 27 by scor-
ing the symptoms: erythema, scarring/dryness, edema, 
and erosion (Fig. 1c). hUCB-MSC-injected groups exhib-
ited decrease in clinical severities after injection. On day 
27, Df-induced mice showed moderate dermatitis scores 
of 5 ± 0.96, and the hUCB-MSC-injected group showed 
decreased scores of 2.6 ± 1.26, or 48% lower than the Df-
induced group. However, the hUCB-MSC + Pime group 
scored 4 ± 0.96, confirming that coadministration did 
not significantly alleviate the clinical severity compared 
to the hUCB-MSC-injected group. These visual obser-
vations indicated that coadministration with pimecroli-
mus hindered the therapeutic effect of hUCB-MSCs on a 
murine AD model.
Pimecrolimus interrupts the therapeutic potential 
of hUCB‑MSCs based on histological and molecular 
analyses of Df‑induced AD in mice
We have further examined the skin; both dorsal and 
ear, and serum of AD mice on day 27. H&E-stained 
dorsal skin samples were investigated to analyze the 
histopathological changes (Fig.  2a). We observed histo-
logical pathologies of experimental AD, including edema 
and epidermal hyperplasia and lymphocyte infiltra-
tion, in Df-induced mice. AD pathologies were attenu-
ated in the hUCB-MSC-injected group. However, little 
attenuation of epidermal pathology was observed in the 
hUCB-MSC + Pime group compared with the hUCB-
MSCs-injected group. Additionally, the ear skin also 
presented the representative histology of AD induced by 
Df, and it displayed a similar pattern to the dorsal skin 
analysis (Additional file 1: Figure S1A). Furthermore, the 
thickness of the epidermis in H&E-stained dorsal skin 
and ear skin was measured (Fig. 2c and Additional file 1: 
S1B). The hUCB-MSC injection resulted in a significant 
decrease of 42.7% in dorsal epidermal thickness, whereas 
the hUCB-MSC + Pime group did not differ from the Df-
induced group (Fig. 2C). The epidermal thickness of ear 
skin also showed a similar trend to the analysis of dor-
sal skin (Figure Additional file  1: S1B). We next evalu-
ated the number of mast cells in the dorsal skin of mice 
using toluidine blue staining (Fig.  2b). Based on tolui-
dine blue-positive cell counts, the hUCB-MSC injection 
significantly suppressed the infiltration of mast cells, 
while coadministration with pimecrolimus countered 
the inhibitory effects of hUCB-MSCs on mast cell infil-
tration (Fig.  2d). We further analyzed the gene expres-
sion levels of chemokines and cytokines in the ear skin 
lesions of the mice to investigate whether pimecrolimus 
altered the immune response (Additional file  1: Fig-
ures S1C and S1D). TARC and IL-22 are related to skin 
inflammation, and their mRNAs are expressed at high 
levels in AD lesions. The single hUCB-MSC treatment 
or pimecrolimus treatment significantly decreased the 
expression levels of TARC and IL-22 mRNAs. However, 
both TARC and IL-22 levels in the hUCB-MSC + Pime 
group returned to the levels of those in the Df-induced 
AD mouse group. We also measured the serum IgE level, 
one of the major hallmarks of AD [19] (Fig.  2e). The 
serum IgE level was significantly decreased by 45% in the 
hUCB-MSC injection group, but the serum IgE level of 
the hUCB-MSC + Pime group was similar to that of Df-
induced group. Taken together, the hUCB-MSC injec-
tion significantly reduced the clinical severity of AD in 
mice, but coadministration of pimecrolimus suppressed 
the therapeutic effects of hUCB-MSCs on a murine AD 
model.
Pimecrolimus has no effect on the cytotoxicity or marker 
expression of hUCB‑MSCs
We first investigated the change in MSC properties 
induced by pimecrolimus to identify the reason why ther-
apeutic effect of hUCB-MSCs is suppressed by pimecroli-
mus. hUCB-MSCs were treated with pimecrolimus for 
72 h to examine the effect of pimecrolimus on the viabil-
ity of hUCB-MSCs using MTT assay. A range of 0.1 ng/
ml–1  μg/ml pimecrolimus did not induce significant 
difference in viability compared with the control group 
(Additional file  2: Figure S2A). Additionally, the admin-
istration of pimecrolimus at concentrations ranging from 
0.01 ng/ml–100 ng/ml did not cause any changes in the 
proliferative capacity (Additional file 2: Figure S2B), cell 
cycle profile (Additional file  2: Figure S2C), or cellular 
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morphology (Additional file 2: Figure S2D). In addition, 
these treatments did not alter the expression levels of 
three positive and three negative MSC markers; CD45, 
CD34, CD36, CD105, CD29 and CD73 (Additional file 2: 
Figure S2E). These findings suggested that pimecrolimus 
did not alter the cellular morphology and biological char-
acteristics of hUCB-MSCs.
Pimecrolimus exerts a suppressive effect 
on the immunomodulatory functions of hUCB‑MSCs
As described above, we determined that coadministra-
tion with pimecrolimus decreased the therapeutic effect 
of the hUCB-MSC treatment, but pimecrolimus was 
not cytotoxic to hUCB-MSCs. Thus, we next examined 
whether pimecrolimus influenced the immunomodula-
tory activity of hUCB-MSCs. hPBMCs were cocultured 
with hUCB-MSCs to evaluate the general immunosup-
pressive property (Fig.  3a). The ConA-induced prolif-
eration of hPBMCs was significantly inhibited when they 
were cocultured with hUCB-MSCs or treated with pime-
crolimus. However, when hPBMCs were coadministered 
with pimecrolimus and hUCB-MSCs simultaneously, 
there was no change in the proliferation of hPBMCs 
compared with control group.
Mast cells are important effector cells in allergic 
responses, and an increased number of mast cells are 
detected in AD skin lesions [20]. Therefore, we investi-
gated whether treatment with pimecrolimus inhibited 
the suppressive effect of hUCB-MSCs on the function 
of mast cells. We cocultured the human mast cell line 
LAD-2 and hUCB-MSCs with pimecrolimus (Fig. 3b–d). 
hUCB-MSCs significantly suppressed the degranula-
tion of mast cells, but coadministration with pimecroli-
mus reduced this effect (Fig.  3b). The proliferation of 
mast cells was decreased in the pimecrolimus-treated 
group and hUCB-MSC coculture group, but the hUCB-
MSC + Pime group did not show a synergistic effect on 
the proliferation of mast cells (Fig.  3c). hMSCs are also 
Fig. 2 Coadministration of pimecrolimus and hUCB‑MSCs inhibits the regulatory effect of hUCB‑MSCs on skin inflammation in Df‑induced AD 
mice. a–d Experimental AD was induced in mice, and skin samples were collected on day 27 for further ex vivo examinations. a Representative 
images of H&E‑stained sections, Bar = 100 μm. b Representative images of toluidine blue‑stained sections, Bar = 100 μm. c Epidermal thickness of 
the dorsal skin was measured in H&E‑stained sections. d The number of mast cells was measured in toluidine blue‑stained sections. e The levels 
of IgE in mouse sera were determined using an ELISA. NC: negative control group, PC: positive control group (Df‑induced group), Pimecrolimus: 
Df‑induction + pimecrolimus, MSC: Df‑induction + hUCB‑MSCs, MSC + Pime.: Df‑induction + hUCB‑MSCs + Pimecrolimus. N = 3–5 mice per group. 
The Kruskal–Wallis test with Dunn’s post hoc test was used to compare other groups with Df‑induced group c–e n.s: not significant, *P < 0.05 and 
**P < 0.01. The results are presented as the means ± SD
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Fig. 3 Pimecrolimus exerts a suppressive effect on the immunomodulatory functions of hUCB‑MSCs in vitro. Cells were treated with 100 ng/
ml pimecrolimus during culture. a The immunosuppressive properties of pimecrolimus‑treated hUCB‑MSCs were determined using the MLR 
assay by measurement of co‑cultured hPBMCs’ proliferation using the BrdU assay. b After coculture with hUCB‑MSCs during the sensitization 
period (24 h), LAD‑2 cells were challenged with anti‑IgE. The degranulation rate of LAD‑2 cells was assessed by detecting β‑hexosaminidase in 
the culture medium. c The proliferation rate of LAD‑2 cells was assessed using the BrdU assay.  d Expression levels of TNF mRNA in LAD‑2 cells 
were determined using Quantitative Real‑time PCR. e The expression of CD4 and IL‑4 was determined using a flow cytometry analysis. Th2: Th2 
cells, Pimecrolimus: Th2 cells treated with pimecrolimus, MSC: Th2 cells cocultured with MSCs, MSC + Pime.: Th2 cells cocultured with MSCs and 
pimecrolimus. f–h Expression levels of the GATA3 (f), STAT6 (g) and IL‑13 (h) mRNAs in Th2 cells were determined using Quantitative Real‑time 
PCR. In vitro experiments were performed in triplicate using hUCB‑MSCs isolated from each donor (N = 3). All experiments shown in this figure 
were analyzed using the Kruskal–Wallis test with Dunn’s post hoc test. n.s: not significant, *P < 0.05 and **P < 0.01. The results are presented as the 
means ± SD
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known to suppress the production of proinflammatory 
cytokines, such as TNF-α, in mast cells [21]. hUCB-
MSC coculture suppressed the expression of the TNF-α 
mRNA, but no suppressive effect was observed in the 
pimecrolimus-treated coculture group (Fig.  3d). Based 
on these results, coadministration of pimecrolimus, when 
cocultured with mast cells, limited the inhibitory effect of 
hUCB-MSCs on mast cells.
As previously reported, Th2 cells predominate in acute 
AD and produce increased levels of related cytokines, 
including IL-4 and IL-13, which induce the production of 
IgE by B cells [22]. Therefore, we investigated the immu-
nomodulatory effects of hUCB-MSCs on lymphocyte 
differentiation and function. We discovered that hUCB-
MSCs and pimecrolimus decreased the differentiation 
rate of  CD4+ IL-4+ Th2 cells, whereas the rate of differ-
entiation to Th2 cells in the hUCB-MSC + Pime group 
with pimecrolimus was as high as that in the Th2 control 
group (Fig.  3e). We also analyzed the gene expression 
levels in Th2 cells after differentiation. Coculture with 
hUCB-MSCs decreased the expression level of GATA3, 
the key transcription factor for Th2 cell differentiation, 
and STAT6, which induces the expression of GATA3 [23, 
24]. However, pimecrolimus inhibited down-regulation 
of the expression of both transcription factors induced 
by hUCB-MSCs (Fig. 3f and g). Additionally, the mRNA 
expression level of IL-13, one of the most important Th2-
type cytokines, was decreased in the hUCB-MSC cocul-
ture group. However, coadministration of hUCB-MSCs 
and pimecrolimus did not change the IL-13 mRNA 
expression level in Th2 cells (Fig.  3h). In summary, we 
determined that the pimecrolimus disturbed the immu-
nomodulatory effect of hUCB-MSCs on cells in the AD 
environment, including Th2 cells and mast cells.
Pimecrolimus reduces  PGE2 production by inhibiting COX2 
expression in hUCB‑MSCs
Various cellular mechanisms are related to hUCB-MSC-
mediated immunomodulation, and secretion of soluble 
factors plays a crucial role [25]. We performed ELISA 
assay to investigate whether pimecrolimus decreases the 
production of factors related to immunomodulation in 
AD, including IDO-1, TGF-beta, and  PGE2. The produc-
tion of IDO-1 by IFN-γ stimulation was not altered by 
pimecrolimus treatment (Additional file  3: Figure S3A). 
The secretion of TGF-beta from hUCB-MSCs was also 
not significantly different after pimecrolimus treatment 
(Additional file 3: Figure S3B). However, treatment with 
pimecrolimus reduced the secretion of  PGE2 in a dose-
dependent manner (Fig. 4a).  PGE2 is one of the essential 
homeostatic factors that plays a key role in MSC-medi-
ated immunomodulation.  PGE2 is synthesized from ara-
chidonic acid released from membrane phospholipids 
by cyclooxygenase (COX) [26]. In our previous stud-
ies, we identified that COX2-PGE2 axis as a crucial fac-
tor responsible for the immunosuppressive properties 
of hUCB-MSCs [11, 27]. Thus, we performed conven-
tional and Quantitative Real-time PCR analysis, and 
found that pimecrolimus dose-dependently decreased 
COX2 mRNA expression level in hUCB-MSCs (Fig.  4b, 
c). The dose-dependent decrease in COX2 expression 
was also confirmed by Western blotting (Fig.  4d), and 
immunostaining analysis also revealed that the COX2 
expression level was decreased by pimecrolimus treat-
ment (Fig.  4e). Based on these findings, pimecrolimus 
decreased the production of  PGE2 as the expression of 
COX2 was dose-dependently suppressed.
Pimecrolimus downregulates the COX2‑PGE2 axis 
by inhibiting the nuclear translocation of NFAT3 
in hUCB‑MSCs
As mentioned above, pimecrolimus inhibits calcineurin 
and prevents the nuclear translocation of NFAT. NFAT 
proteins or their mRNAs have been detected outside the 
immune system, suggesting their possible involvement in 
the development or function of other systems [28]. Next, 
we hypothesized that pimecrolimus inhibits the COX2-
PGE2 axis in hUCB-MSCs by regulating NFAT transloca-
tion. First, we screened which of the five members of the 
NFAT family were expressed in hUCB-MSCs. We per-
formed a conventional RT-PCR analysis of the five NFAT 
family members to evaluate their mRNA expression lev-
els in hUCB-MSCs (Fig. 5a). RNA extracted from hUCB-
MSCs was analyzed in parallel with RNA from whole 
hPBMCs or isolated T cells from hPBMCs. The mRNA 
expression of FKBP12, a protein to which pimecrolimus 
binds that regulates NFAT activation, was confirmed 
in hUCB-MSCs. NFAT1 and NFAT2 mRNA expres-
sions were not detected in hUCB-MSCs, whereas these 
mRNAs were expressed in hPBMCs and T cells, as previ-
ously described [29]. Although variations were observed 
between cell lines, the expression of NFAT3, NFAT4 and 
NFAT5 was detected in hUCB-MSCs. We focused on 
NFAT3 because its expression was confirmed in all 3 lines 
of hUCB-MSCs. Next, we investigated whether pime-
crolimus blocked the nuclear translocation of NFAT3. 
In the vehicle group, NFAT3 was detected in both the 
nucleus and cytosol, but it was predominantly located in 
the nuclear fraction (Fig.  5b). Interestingly, NFAT3 was 
mostly located in the cytosolic fraction of hUCB-MSCs 
after pimecrolimus treatment. Western blot analysis of 
subcellular fractions from hUCB-MSCs also showed 
that the expression of NFAT3 in the nuclear localization 
decreased dose-dependently by pimecrolimus treatment 
(Fig.  5c, e). The expression of NFAT3 in the cytosolic 
fraction, conversely, increased by pimecrolimus (Fig. 5d, 
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e). A subsequent decrease in COX2 levels in cytosolic 
fraction was observed (Fig.  5d). Coactivation of cells 
with ionomycin and phorbol myristate acetate (PMA) is 
known to result in a significant upregulation of NFAT-
dependent gene expression by inducing the dephospho-
rylation of NFAT. Next, hUCB-MSCs were treated with 
ionomycin/PMA. Although NFAT3 was detected in both 
the cytosol and nucleus in resting hUCB-MSCs, ionomy-
cin/PMA accelerated the nuclear translocation of NFAT3 
and increased COX2 expression (Fig.  5f ). Thus, COX2 
expression in hUCB-MSCs depended on NFAT3 signal-
ing. Additionally, by performing a Western blot analysis, 
we confirmed that the level of COX2 was increased by 
treatment with ionomycin/PMA, and the level of COX2 
in pimecrolimus-treated hUCB-MSCs was decreased 
under both resting and ionomycin/PMA-treated con-
ditions (Fig.  5g). These results suggested that NFAT 
activation by ionomycin/PMA increased COX2 expres-
sion and that pimecrolimus inhibited COX2 expression. 
We further analyzed the phosphorylation of NFAT3. 
NFAT must be dephosphorylated for activation in the 
nucleus, and thus phosphorylated NFAT indicates a 
cytosolic localization. After treatment with pimecroli-
mus, the level of phosphorylated NFAT3 was increased. 
When hUCB-MSCs were treated with ionomycin/PMA, 
the level of phosphorylated NFAT3 was decreased, indi-
cating a reduction in the cytosolic localization of NFAT3. 
However, after treatment with pimecrolimus, the level 
of phosphorylated NFAT3 was increased in both rest-
ing and ionomycin/PMA-treated hUCB-MSCs. Taken 
together, these observations indicate that NFAT3 is one 
of the crucial transcription factors in hUCB-MSCs that 
induced COX2 expression and pimecrolimus administra-
tion interfered with its function.
Fig. 4 Pimecrolimus reduces  PGE2 production by regulating COX2 expression in hUCB‑MSCs. hUCB‑MSCs were treated with a–d the indicated 
concentration or e 100 ng/ml of pimecrolimus for 72 h. a The levels of  PGE2 in the cell culture supernatant of hUCB‑MSCs were determined using an 
ELISA. B–c The expression of the COX2 mRNA was determined using b conventional PCR and c Quantitative Real‑time PCR. d Western blotting data 
and quantification showed the relative expression levels of COX2 in hUCB‑MSCs. Expression of COX2 was normalized against GAPDH housekeeping 
gene by ImageJ program. e The expression of COX2 in hUCB‑MSCs was verified by immunostaining, Bar = 500 μm. In vitro experiments were 
performed in triplicate using hUCB‑MSCs isolated from each donor (N = 3). The Kruskal–Wallis test with Dunn’s post hoc was used to compare 
the pimecrolimus‑treated hUCB‑MSCs with control group. n.s: not significant, *P < 0.05, **P < 0.01 and ***P < 0.001, ****P < 0.0001. The results are 
presented as the means ± SD
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Discussion
AD is a chronic and inflammatory cutaneous disease that 
results from complex genetic, epigenetic, environmental 
and immunological interactions with an overlapping epi-
dermal barrier defect [30]. The treatment of AD is based 
on emollients, anti-inflammatory drugs, antihistamines 
and antibiotics. Many patients have already been pre-
scribed to use drugs in combination. Combination ther-
apy is particularly beneficial when it provides additive or 
synergistic efficacy, often reducing the required doses of 
Fig. 5 Pimecrolimus downregulates the COX2‑PGE2 axis in hUCB‑MSCs by inhibiting nuclear localization of NFAT3. a The mRNA expression of 
NFAT isoforms and FKBP1 was determined using conventional PCR. hPBMCs or T cells were used as positive controls. b The expression of the NFAT3 
in hUCB‑MSCs was verified by immunostaining, Bar = 200 μm. Cells were treated with pimecrolimus (100 ng/ml). c–e Nuclear (c) and Cytosolic 
(d) fractions were analyzed using Western blotting. hUCB‑MSCs were treated with the indicated concentration of pimecrolimus for 3 days. The 
specificity of the nuclear and cytosolic extracts was determined by performing Western blot analysis with lamin A/C (nuclear) and α‑tubulin 
(cytoplasmic) antibodies. Quantification of NFAT3 and cytosolic COX2 was performed by Image J, and normalized by lamin A/C (nuclear fraction) 
or α‑tubulin (cytosolic fraction). The graph e represents the relative expression level of NFAT3 in nucleus and cytosol of hUCB‑MSCs dependent 
on pimecrolimus treatment. f The expression of NFAT3 and COX2 in hUCB‑MSCs. Cells were treated with ionomycin (1 μg/ml) and PMA (100 ng/
ml) for 72 h. Bar = 200 μm. g Western blot analysis of hUCB‑MSCs revealed COX2 expression and NFAT phosphorylation. Cells were treated with 
ionomycin (1 μg/ml) and PMA (100 ng/ml) for 72 h with or without pimecrolimus (100 ng/ml). Quantification of COX2 and phosphorylated NFAT3 
was performed by imageJ. Expression of COX2 was normalized against GAPDH housekeeping gene, and expression of phosphorylated NFAT3 was 
normalized against NFAT3 and GAPDH housekeeping gene. The Kruskal–Wallis test with Dunn’s post hoc was used in (e). *P < 0.05 and **P < 0.01. 
In vitro experiments were performed in triplicate using hUCB‑MSCs isolated from each donor (N = 3)
Page 13 of 16Shin et al. Stem Cell Res Ther          (2021) 12:482  
each drug compared with monotherapy and potentially 
limiting side effects. However, not all drug combinations 
work well, and may lead to the inactivation of other drugs 
or an exacerbation of side effects in some cases. There-
fore, the combination of drugs should be confirmed to 
exert complementary effects rather than antagonistic or 
redundant effects [31]. In terms of mesenchymal stem 
cells, several studies suggest enhancement strategies 
via combination therapy with other agents. For exam-
ple, coadministration with graphene oxide flakes or the 
immunomodulatory microparticle MIS416, has been 
reported to enhance the implantation of MSCs into the 
lesion [32, 33]. Although many studies have focused on 
resolving the limitations of hMSCs therapy, however 
researchers have not reported whether a combination 
method disrupts the therapeutic potential of mesenchy-
mal stem cells. Therefore, we focused on the interaction 
of hUCB-MSCs and a topical calcineurin inhibitor, one of 
the most common anti-inflammatory drugs used to treat 
AD.
In this study, coadministration with pimecrolimus 
reduced the therapeutic effects of hUCB-MSCs on AD. 
Pimecrolimus cream (1%), a topical calcineurin inhibitor, 
has been used to treat AD. Pimecrolimus targets T cells 
and mast cells and inhibits the production and release 
of cytokines and other inflammatory mediators [34]. It 
binds with high affinity to FKBP12 and inhibits the activ-
ity of calcineurin, a calcium-dependent phosphatase. 
Calcineurin dephosphorylates NFAT, one of the most 
important transcription factors in T cells, and induces its 
translocation into the nucleus and activation. Therefore, 
pimecrolimus inhibits calcineurin-mediated NFAT acti-
vation in T cells, resulting a blockade of the transcription 
of inflammatory cytokines. Several studies on the effects 
of calcineurin inhibitors on the other cell types, in addi-
tion to T cells, have been reported [35–37]. NFAT tran-
scription factors play a key role in T cell activation and 
differentiation. Recent studies have revealed that they 
also play an important role in other immune cell types, 
including dendritic cells, mast cells, B cells, natural killer 
T cells and megakaryocytes [38–40]. NFAT proteins are 
also involved in various developmental processes, includ-
ing those of the heart, skeletal muscle, smooth muscle, 
vasculature, neurons, bone, pancreas and skin [41]. The 
NFAT family consists of five proteins: NFAT1 (NFATc2), 
NFAT2 (NFATc1), NFAT3 (NFATc4), NFAT4 (NFATc3), 
and NFAT5 [42]. NFAT1 and NFAT2 are the major 
NFATs involved in T cell activation, NFAT3 is expressed 
primarily in nonlymphoid tissues, NFAT4 is expressed 
mainly in the thymus, and NFAT5 is a transcription fac-
tor crucial for cellular response to hypertonic stress [28]. 
We first identified the expression of the NFAT family 
and FKBP12 in hUCB-MSCs. Among the 5 NFAT family 
members, only NFAT3 was expressed in all 3 hUCB-MSC 
lines, and NFAT4 was also expressed in one cell line. 
Notably, NFAT3 proteins are partially constitutively 
active in hUCB-MSCs, even in resting cells, as judged by 
their subcellular localization. This result suggested that 
NFAT3 may mediate the transcription of some genes in 
hUCB-MSCs.
We observed that pimecrolimus treatment inhibited the 
nuclear translocation of NFAT3 and downregulated the 
expression of COX2, suggesting an involvement of NFAT 
in the transcription of the COX2 gene. The human COX2 
promoter contains binding sites for NF-κB, NF-IL6, CRE 
binding proteins, and NFAT [43]. The induction of COX2 
expression by NFAT has been reported in human T cells, 
breast cancer cells, keratinocytes and vascular smooth 
muscle cells [43–46]. However, our study is the first to 
identify the induction of COX2 expression by NFAT in 
human mesenchymal stem cells, and more importantly, 
we showed that the combination of pimecrolimus and 
hMSC therapy potentially leads to an antagonized result.
hMSCs have been known to exert immunomodulatory 
functions via several soluble factors including TGF-beta, 
HGF, IL-6, IL-10, NO and  PGE2 [47]. Among these fac-
tors,  PGE2 is an especially important soluble factor that 
attenuates the crucial phenotype of AD progression. It 
is known to regulate many immune cells associated with 
AD, including T cells, monocytes, B cells and NK cells 
[48]. Thus, COX2, a key enzyme involved in the produc-
tion of  PGE2, is also considered a crucial indicator of the 
immunomodulatory efficacy of hUCB-MSCs [49]. Shin 
et  al. and Lee et  al. reported that hMSCs exert inhibi-
tory effects on IgE production by B cells, but these effects 
were attenuated by celecoxib, a selective COX2 inhibitor. 
Inhibition of mast cell degranulation by hMSCs has also 
been reported to be mediated by COX2-PGE2 pathway, 
and hMSCs treated with celecoxib exert a weak inhibi-
tory effect on mast cell degranulation [12, 16]. Addi-
tionally, in our study, pimecrolimus downregulated the 
expression level of COX2 in hUCB-MSC, and hUCB-
MSCs treatment with pimecrolimus did not induce 
immunosuppression against Th2 cells and mast cells than 
control group. Taken together, these results imply that 
the COX2-PGE2 axis is critical for hUCB-MSCs to exert 
their immunosuppressive function against AD.
The present study revealed that coadministration 
with pimecrolimus hindered the therapeutic effects of 
hUCB-MSCs on AD by inhibiting COX2 expression via 
the NFAT-COX2-PGE2 axis. As the therapeutic use of 
human mesenchymal stem cells has become more wide-
spread, interactions with other drugs should be eluci-
dated for safety and efficacy issues. We first documented 
that pimecrolimus influenced the effectiveness of hMSC 
therapy in AD in animal models and in vitro. Thus, from 
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the perspective of hMSC therapy, we suggest that cal-
cineurin inhibitors, especially pimecrolimus, should be 
used under appropriate medical oversight. This finding 
could be a vital factor behind the unsatisfactory results 
in clinical trials of hMSC therapy. For more efficient and 
definite curative effects, an adjustment of medication 
period might be suggested as a solution. Furthermore, 
current mainstay treatments for AD include a large vari-
ety of drugs, such as topical corticosteroids, antihista-
mines or antibiotics. In our previous study, histamine 
played a role in the COX2-mediated immunomodula-
tory ability of hUCB-MSCs through the activation of its 
receptors H1 and H4 [16]. This result implied that coad-
ministration of antihistamine and hUCB-MSC therapy 
might affect the therapeutic outcome. Therefore, studies 
elucidating the interaction with other drugs and hMSCs 
might facilitate the improvement of clinical applications 
and expand our knowledge regarding the mechanisms of 
hMSC therapy for AD.
Conclusions
hMSCs therapy holds considerable promise as an alter-
native therapeutic reagent for allergic disorders including 
AD. However, it is unclear whether combination strat-
egy with other drugs might affect the result of cellular 
therapy. In the current study, we identified that pime-
crolimus, one of the most common prescriptions for AD, 
could suppress the therapeutic potential of hMSC ther-
apy. Further, we identified that pimecrolimus regulates 
the nuclear translocation of NFAT, and NFAT acts as a 
transcription factor for COX2 which is a crucial factor of 
immunomodulation of hMSCs. Our approach for combi-
nation therapy offers possibilities that simultaneous use 
of other drugs with hMSCs could influence the therapeu-
tic outcomes of cell therapy and provides the improve-
ment of the clinical application.
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Additional file 1. Figure S1: Coadministration of hUCB‑MSCs and 
pimecrolimus inhibits the regulatory effect on atopic dermatitis in ear 
lesions. (A) Representative images of H&E‑stained sections of ear lesions, 
Bar = 100 μm. (B) The thickness of the ear was measured in H&E‑stained 
sections. (C‑D) Expression levels of the TARC (C) and IL‑22 (D) mRNAs 
in ear lesions were determined using Quantitative Real‑time PCR. NC: 
negative control group, PC: positive control group (Df‑induced group), 
Pimecrolimus: Df‑induction + pimecrolimus, MSC: Df‑induction + hUCB‑
MSCs, MSC+Pime.: Df‑induction + hUCB‑MSCs + pimecrolimus. The 
Kruskal‑Wallis test with Dunn’s post hoc test was used to compare other 
groups with the Df‑induced group (B‑D). N = 3−5 mice per group. n.s: not 
significant and *P<0.05. The results are presented as the means ± SD.
Additional file 2. Figure S2: Pimecrolimus does not alter the fundamen‑
tal properties of hUCB‑MSCs. hUCB‑MSCs were treated with the indicated 
concentrations of pimecrolimus for 3 days, and further analyses were 
conducted. (A) Analysis of cell viability using the MTT assay. (B) Represent‑
ative bright‑field microscopy images of hUCB‑MSCs, Bar = 500 μm. (C) The 
proliferation of hUCB‑MSCs was determined using the BrdU assay. (D) Cell 
cycle assay. (E) Cell surface marker expression on hUCB‑MSCs. The expres‑
sion profile of cell surface markers in hUCB‑MSCs was measured using 
flow cytometry analysis. Negative markers: CD45, CD34 and CD36. Positive 
markers: CD105, CD29 and CD73. Histograms show a representative 
result. In vitro experiments were performed in triplicate using hUCB‑MSCs 
isolated from each different donor (N=3). The Kruskal‑Wallis test with 
Dunn’s post hoc test was used to compare treated cells with nontreated 
cells. (A‑B). n.s: not significant and ****P<0.0001. The results are presented 
as the means ± SD.
Additional file 3. Figure S3: Pimecrolimus does not influence the 
production of TGF‑beta and IDO‑1 from hUCB‑MSCs. hUCB‑MSCs were 
treated with indicated concentration of pimecrolimus for 3 days. (A) To 
measure the production of IDO‑1 in hUCB‑MSCs, cells were treated with 
pimecrolimus and IFN‑γ (20 ng/ml). The levels of IDO‑1 (cell lysates) from 
hUCB‑MSCs were determined by ELISA. (B) After pimecrolimus treatment, 
the secretion of TGF‑beta (cell supernatant) from hUCB‑MSCs was deter‑
mined by ELISA. In vitro experiments were performed in triplicate using 
hUCB‑MSCs isolated from each different donor (N=3). All experiments in 
this figure were analyzed using the Kruskal‑Wallis test with Dunn’s post 
hoc test. n.s: not significant. Results are shown as the mean ± SD.
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